Adjuvant Chemoradiation Therapy for Pancreatic Adenocarcinoma: Who Really Benefits?

BACKGROUND: The role of adjuvant chemoradiation therapy (CRT) in pancreatic cancer remains controversial. The primary aim of this Study was to determine if CRT improved survival in patients with resected pancreatic cancer in a large, multiinstitutional cohort of patients. STUDY DESIGN: patients undergoing resection for pancreatic adenocarcinoma from seven academic medical institutions were included,. Exclusion criteria included Patients with T4 or M1 disease, R2 resection margin, preoperative therapy, chemotherapy alone, or if adjuvant therapy status Was unknown. RESULTS: There were 747 patients included in the Initial evaluation. Primary analysis was performed between patients that had Surgery alone (n = 374) and those receiving adjuvant CRT (n = 299). Median followup time was 12.2 months and 14.5 months for Survivors. Median overall survival for patients receiving adjuvant CRT was significantly longer than for those undergoing operation alone (20.0 Months Versus 14.5 months, p = 0.001). Oil Subset and multivariate analysis, adjuvant CRT demonstrated a significant Survival advantage only among patients who had lymph node (LN)-positive disease (hazard ratio 0.477, 95% CI 0.357 to 0.638) and not for LN-negative patients (hazard ratio 0.810, 95% CI 0.556 to 1.18 1). Disease-free Survival in patients with LN-negative discase who received adjuvant CRT was significantly worse than in patients who had surgery alone (14.5 months versus 18.6 months, p = 0.034). CONCLUSIONS: This large multiinstitutional study emphasizes the Importance of analyzing Subsets of patients With pancreas adenocarcinoma who have LN metastasis. Benefit of adjuvant CRT is seen only tit patients with LN-positive disease, regardless of resection margin status. CRT in patients with LN-negative disease may contribute to reduced disease-free survival. (J Am Coll Surg, 2009; 208:829-841. (C) 2009 by the American College Of Surgeons)